Abhijit Lele &Amp; Sohini Das

Stories by Abhijit Lele &Amp; Sohini Das

Mankind Pharma Targets Anti-Obesity Drug

Mankind Pharma Targets Anti-Obesity Drug

Rediff.com   6 Mar 2025

'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'

Can Tesla Make In India For Below $23,000?

Can Tesla Make In India For Below $23,000?

Rediff.com   5 Mar 2025

The Indian automotive market offers around 1 million units annual volume opportunity at a price above $23,000.

Gold loan offtake stays strong amid retail loan moderation in January

Gold loan offtake stays strong amid retail loan moderation in January

Rediff.com   1 Mar 2025

The gold loan portfolio of banks continued to show strong off-take with 76 per cent year-on-year (Y-o-Y) growth in January 2025 amid moderation in retail credit - especially in the unsecured credit segment - following increase in risk weights in November 2023. The gold loan pool had grown 17.4 per cent Y-o-Y in January 2024.

India Inc holds breath for Trump's new tariffs to kick in

India Inc holds breath for Trump's new tariffs to kick in

Rediff.com   27 Feb 2025

Industry insiders in India warn that any such move in the pharmaceutical sector could be counterproductive for the US as it may face increased drug shortages if tariffs are imposed on such imports.

'How Will I Survive Without My Monthly Withdrawals?'

'How Will I Survive Without My Monthly Withdrawals?'

Rediff.com   24 Feb 2025

'I don't know when I will be able to access those funds.'

Why Tesla Entry is No Major Threat

Why Tesla Entry is No Major Threat

Rediff.com   24 Feb 2025

Tesla needs to either sell the same models with reduced features to lower the cost for Indian market, or incur losses.

USAID Funding To India Declines Amid Trump's Freeze

USAID Funding To India Declines Amid Trump's Freeze

Rediff.com   13 Feb 2025

'If the Bill and Melinda Gates Foundation cuts funds, there could be more impact.'

Highest Selling New Drug In India Is...

Highest Selling New Drug In India Is...

Rediff.com   11 Feb 2025

Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection.

'Tariffs will hurt insurance, patients and everyone'

'Tariffs will hurt insurance, patients and everyone'

Rediff.com   10 Feb 2025

After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like basis, Siddharth Mittal, chief executive officer (CEO) and managing director, Biocon, told Sohini Das/Business Standard in a virtual interaction that local manufacturing in the US is a trade off between cost and qualifying to do business there.

Budget Prepares For Rise In Cancer Cases

Budget Prepares For Rise In Cancer Cases

Rediff.com   3 Feb 2025

Do we have enough trained oncologists and medical professionals in India to man these over 4,500 beds in the public sector?

Trump's Tariff War: India Waits, Watches

Trump's Tariff War: India Waits, Watches

Rediff.com   3 Feb 2025

'We have to be prepared for the larger disruption that is likely to take place.'

GBS Disease: 16 Patients On Ventilator

GBS Disease: 16 Patients On Ventilator

Rediff.com   27 Jan 2025

Water samples from different parts of Pune have been sent to the public health laboratory for chemical and biological analysis.

Rupee Slide: Tough Times For Overseas Corporate Debt

Rupee Slide: Tough Times For Overseas Corporate Debt

Rediff.com   16 Jan 2025

Raising overseas debt has become prohibitively expensive due to the depreciating rupee.

New Tata EVs will run 500 km on single charge

New Tata EVs will run 500 km on single charge

Rediff.com   13 Jan 2025

As battery prices drop, early customers of Tata Motors, which was the first mover in the passenger EV market, could feel let down.

Broad-based corporate capex recovery unlikely in FY26: India Ratings

Broad-based corporate capex recovery unlikely in FY26: India Ratings

Rediff.com   10 Jan 2025

India Ratings on Thursday said that any broad-based or strong recovery in corporate capital expenditure was unlikely in the upcoming financial year 2026 (FY26) due to uncertainty of domestic and external demand. The uncertainty is adversely affecting the overall corporate sector capex. Interest rates on credit are not the primary deterrent to decisions about capital expenditure, said Soumyajit Niyogi, director, core analytical group, Ind-Ra, in a webinar on the credit market outlook.

How is Tata Motors gearing up to face competition?

How is Tata Motors gearing up to face competition?

Rediff.com   8 Jan 2025

Why is Shailesh Chandra, managing director of Tata Motors Passenger Vehicles and Tata Passenger Electric Mobility, not worried about the competition?

Tata Punch Knocks Out Maruti!

Tata Punch Knocks Out Maruti!

Rediff.com   7 Jan 2025

While Maruti held the top spot for four decades, the Ambassador was the best-selling car in post-Independence India for three decades.

Honda-Nissan Merger: What About India?

Honda-Nissan Merger: What About India?

Rediff.com   24 Dec 2024

Two Japanese auto giants, Honda and Nissan, are moving towards a potential merger, but it remains unclear how their Indian operations will be immediately impacted.

This is one of the largest health-care deals in India

This is one of the largest health-care deals in India

Rediff.com   13 Dec 2024

'Along with Blackstone, we would be keen to look at opportunities in the North.'

Will Skoda's New SUV Kylaq Make It big?

Will Skoda's New SUV Kylaq Make It big?

Rediff.com   12 Dec 2024

The company is eyeing sales of 8,000 units per month for the Kylaq, which starts at Rs 7.89 lakh (ex-showroom) and boasts 96 per cent localisation.